Select a category to find the resources you need.

All Resources All Resources All Resources All Resources

All
Resources

All Resources All Resources All Resources All Resources

Patient
Education

All Resources All Resources All Resources All Resources

In-Office
Materials

All Resources All Resources All Resources All Resources

Reimbursement

Filter by:

All Resources

All Indications

Wet AMD

DME

DR

MEfRVO

All

Patient Tools

Learn About Conditions

Financial Support

Lifestyle Support

All

Forms & Letters

Guides & Flashcards

Videos

All

Billing & Coding

CMS

EYLEA4U®

All Resources

Clear

All Indications

The Amsler Grid, with instructions, is provided by Regeneron to help people monitor their vision.

EmailEmail

This flashcard can help aid the reimbursement process by providing codes relevant to EYLEA for the treatment of Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Wet Age-related Macular Degeneration (AMD), or Macular Edema following Retinal Vein Occlusion (MEfRVO).

EmailEmail

This tip sheet provides helpful information and resources for caregivers of someone living with Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), or Macular Edema following Retinal Vein Occlusion (MEfRVO).

EmailEmail

This flashcard includes examples of the CMS 1450 form used by hospital outpatient departments and the CMS 1500 form used by physician offices for Medicare billing.

EmailEmail

A reimbursement resource explaining the information needed to complete the EYLEA4U Enrollment Form and understand the results report of a Benefit Investigation (BI).

EmailEmail

This video provides information on the preparation of EYLEA vial for intravitreal administration.

Planning to use this video in your office or post on your office website? Please refer to the requirements document here and in the files provided to you after downloading this video.

PlayPlay

EmailEmail

This tip sheet provides helpful lifestyle information designed to help people with low vision.

EmailEmail

A helpful checklist of questions that patients can ask their eye care team during their first visit. Includes questions about vision changes that may be signs of certain retinal diseases, such as Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Wet Age-related Macular Degeneration (AMD), or Macular Edema following Retinal Vein Occlusion (MEfRVO).

EmailEmail

A checklist of questions patients can ask their eye care team at every visit. Includes questions about visual acuity, vision monitoring, eye treatments, and living with low vision.

EmailEmail

A brochure that explains the resources available to eligible patients through EYLEA4U®—a comprehensive patient support program.

EmailEmail

FDA letter granting Regeneron Pharmaceuticals, Inc. approval of the use of EYLEA in a pre-filled syringe (PFS).

EmailEmail

This video provides step-by-step information on the preparation of the EYLEA single-dose, pre-filled syringe (PFS) for intravitreal administration.

Planning to use this video in your office or post on your office website? Please refer to the requirements document here and in the files provided to you after downloading this video.

PlayPlay

EmailEmail

This letter provides an example of the types of information that may be provided when appealing a bilateral injection denial from a patient’s health plan for EYLEA treatment.

EmailEmail

This letter provides an example of the types of information that may be provided when appealing a claims denial from a patient’s health plan for EYLEA treatment.

EmailEmail

This letter provides an example of the types of information that may be provided when appealing a prior authorization denial from a patient’s health plan for EYLEA treatment.

EmailEmail

This letter provides an example of the types of information that may be provided when responding to a request from a patient’s health plan to provide a letter of medical necessity for EYLEA treatment.

EmailEmail

This letter provides an example of the types of information that may be provided when responding to a step-edit request from a patient’s health plan to provide a letter of medical necessity for EYLEA treatment.

EmailEmail

This form allows physicians to enroll patients in EYLEA4U® and request support, including a Benefit Investigation (BI), appeals support, prior authorization (PA), and claims assistance.

English

EmailEmail

The form allows physicians and their Spanish-speaking patients to enroll in EYLEA4U® and request support, including a Benefits Investigation (BI), appeals support, prior authorization (PA), and claims assistance.

Spanish

EmailEmail

Wet AMD

This booklet provides an overview of the 52-week results of the VIEW 1 and VIEW 2 clinical trials of EYLEA in Wet AMD. Includes case examples from the VIEW 1 trial at 52 weeks.

EmailEmail

This letter provides an example of the types of information that may be provided when appealing a dosing denial from a patient’s health plan for EYLEA.

EmailEmail

FDA letter granting Regeneron Pharmaceuticals, Inc. approval of EYLEA for the treatment of Wet AMD.

EmailEmail

A patient education brochure that explains what Wet AMD is, who it affects, how it can affect vision, and treatment with EYLEA.

English

EmailEmail

A Spanish-language patient education brochure that explains what Wet AMD is, who it affects, how it can affect vision, and treatment with EYLEA.

Spanish

EmailEmail

A patient education video that explains what Wet AMD is and how it occurs, symptoms of Wet AMD, vision tests to detect it, the importance of regular eye exams and following an eye care specialist’s treatment plan.

Planning to use this video in your office or post on your office website? Please refer to the requirements document here and in the files provided to you after downloading this video.

PlayPlay

EmailEmail

DME

FDA letter granting Regeneron Pharmaceuticals, Inc. approval of EYLEA for the treatment of DME.

EmailEmail

A patient education brochure that explains what Diabetic Macular Edema (DME) is, who it affects, how it can affect vision, and treatment with EYLEA.

English

EmailEmail

A Spanish-language patient education brochure that explains what Diabetic Macular Edema (DME) is, who it affects, how it can affect vision, and treatment with EYLEA.

Spanish

EmailEmail

This booklet provides an overview of the 52- and 100-week results of the VISTA and VIVID clinical trials of EYLEA in DME. Includes case examples from the VISTA trial at 100 weeks.

EmailEmail

A patient education video that explains what DME is and how it occurs, symptoms of DME, vision tests to detect it, the importance of regular eye exams and following an eye care specialist’s treatment plan.

Planning to use this video in your office or post on your office website? Please refer to the requirements document here and in the files provided to you after downloading this video.

PlayPlay

EmailEmail

DR

FDA letter granting Regeneron Pharmaceuticals, Inc. approval of EYLEA for the treatment of DR.

EmailEmail

FDA letter granting Regeneron Pharmaceuticals, Inc. approval of EYLEA for the treatment of DR in patients with DME.

EmailEmail

A patient education brochure that explains what DR is, who it affects, how it can affect vision and progress, and treatment with EYLEA.

EmailEmail

A Spanish-language patient education brochure that explains what DR is, who it affects, how it can affect vision and progress, and treatment with EYLEA.

Spanish

EmailEmail

MEfRVO

FDA letter granting Regeneron Pharmaceuticals, Inc. approval of EYLEA for the treatment of MEfRVO.

EmailEmail

FDA letter granting Regeneron Pharmaceuticals, Inc. approval of EYLEA for the treatment of MEfCRVO.

EmailEmail

A patient education brochure that explains what MEfRVO is, who it affects, how it can affect vision, and treatment with EYLEA.

English

EmailEmail

A Spanish-language patient education brochure that explains what MEfRVO is, who it affects, how it can affect vision, and treatment with EYLEA.

Spanish

EmailEmail

Patient Education

Clear

Patient Tools

The Amsler Grid, with instructions, is provided by Regeneron to help people monitor their vision.

EmailEmail

Learn About Conditions

All Indications

A helpful checklist of questions that patients can ask their eye care team during their first visit. Includes questions about vision changes that may be signs of certain retinal diseases, such as Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Wet Age-related Macular Degeneration (AMD), or Macular Edema following Retinal Vein Occlusion (MEfRVO).

EmailEmail

A checklist of questions patients can ask their eye care team at every visit. Includes questions about visual acuity, vision monitoring, eye treatments, and living with low vision.

EmailEmail

Wet AMD

A patient education brochure that explains what Wet AMD is, who it affects, how it can affect vision, and treatment with EYLEA.

English

EmailEmail

A Spanish-language patient education brochure that explains what Wet AMD is, who it affects, how it can affect vision, and treatment with EYLEA.

Spanish

EmailEmail

A patient education video that explains what Wet AMD is and how it occurs, symptoms of Wet AMD, vision tests to detect it, the importance of regular eye exams and following an eye care specialist’s treatment plan.

Planning to use this video in your office or post on your office website? Please refer to the requirements document here and in the files provided to you after downloading this video.

PlayPlay

EmailEmail

DME

A patient education brochure that explains what Diabetic Macular Edema (DME) is, who it affects, how it can affect vision, and treatment with EYLEA.

English

EmailEmail

A Spanish-language patient education brochure that explains what Diabetic Macular Edema (DME) is, who it affects, how it can affect vision, and treatment with EYLEA.

Spanish

EmailEmail

A patient education video that explains what DME is and how it occurs, symptoms of DME, vision tests to detect it, the importance of regular eye exams and following an eye care specialist’s treatment plan.

Planning to use this video in your office or post on your office website? Please refer to the requirements document here and in the files provided to you after downloading this video.

PlayPlay

EmailEmail

DR

A patient education brochure that explains what DR is, who it affects, how it can affect vision and progress, and treatment with EYLEA.

EmailEmail

A Spanish-language patient education brochure that explains what DR is, who it affects, how it can affect vision and progress, and treatment with EYLEA.

Spanish

EmailEmail

MEfRVO

A patient education brochure that explains what MEfRVO is, who it affects, how it can affect vision, and treatment with EYLEA.

English

EmailEmail

A Spanish-language patient education brochure that explains what MEfRVO is, who it affects, how it can affect vision, and treatment with EYLEA.

Spanish

EmailEmail

Financial Support

A brochure that explains the resources available to eligible patients through EYLEA4U®—a comprehensive patient support program.

EmailEmail

Lifestyle Support

This tip sheet provides helpful information and resources for caregivers of someone living with Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), or Macular Edema following Retinal Vein Occlusion (MEfRVO).

EmailEmail

This tip sheet provides helpful lifestyle information designed to help people with low vision.

EmailEmail

In-office Materials

Clear

Forms & Letters

This flashcard includes examples of the CMS 1450 form used by hospital outpatient departments and the CMS 1500 form used by physician offices for Medicare billing.

EmailEmail

FDA letter granting Regeneron Pharmaceuticals, Inc. approval of EYLEA for the treatment of DME.

EmailEmail

FDA letter granting Regeneron Pharmaceuticals, Inc. approval of EYLEA for the treatment of DR.

EmailEmail

FDA letter granting Regeneron Pharmaceuticals, Inc. approval of EYLEA for the treatment of DR in patients with DME.

EmailEmail

FDA letter granting Regeneron Pharmaceuticals, Inc. approval of EYLEA for the treatment of MEfRVO.

EmailEmail

FDA letter granting Regeneron Pharmaceuticals, Inc. approval of EYLEA for the treatment of MEfCRVO.

EmailEmail

FDA letter granting Regeneron Pharmaceuticals, Inc. approval of the use of EYLEA in a pre-filled syringe (PFS).

EmailEmail

This letter provides an example of the types of information that may be provided when appealing a dosing denial from a patient’s health plan for EYLEA.

EmailEmail

This letter provides an example of the types of information that may be provided when appealing a bilateral injection denial from a patient’s health plan for EYLEA treatment.

EmailEmail

This letter provides an example of the types of information that may be provided when appealing a claims denial from a patient’s health plan for EYLEA treatment.

EmailEmail

This letter provides an example of the types of information that may be provided when appealing a prior authorization denial from a patient’s health plan for EYLEA treatment.

EmailEmail

This letter provides an example of the types of information that may be provided when responding to a request from a patient’s health plan to provide a letter of medical necessity for EYLEA treatment.

EmailEmail

This letter provides an example of the types of information that may be provided when responding to a step-edit request from a patient’s health plan to provide a letter of medical necessity for EYLEA treatment.

EmailEmail

This form allows physicians to enroll patients in EYLEA4U® and request support, including a Benefit Investigation (BI), appeals support, prior authorization (PA), and claims assistance.

English

EmailEmail

The form allows physicians and their Spanish-speaking patients to enroll in EYLEA4U® and request support, including a Benefits Investigation (BI), appeals support, prior authorization (PA), and claims assistance.

Spanish

EmailEmail

FDA letter granting Regeneron Pharmaceuticals, Inc. approval of EYLEA for the treatment of Wet AMD.

EmailEmail

Guides & Flashcards

The Amsler Grid, with instructions, is provided by Regeneron to help people monitor their vision.

EmailEmail

A reimbursement resource explaining the information needed to complete the EYLEA4U Enrollment Form and understand the results report of a Benefit Investigation (BI).

EmailEmail

A helpful checklist of questions that patients can ask their eye care team during their first visit. Includes questions about vision changes that may be signs of certain retinal diseases, such as Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Wet Age-related Macular Degeneration (AMD), or Macular Edema following Retinal Vein Occlusion (MEfRVO).

EmailEmail

A checklist of questions patients can ask their eye care team at every visit. Includes questions about visual acuity, vision monitoring, eye treatments, and living with low vision.

EmailEmail

Videos

This video provides information on the preparation of EYLEA vial for intravitreal administration.

Planning to use this video in your office or post on your office website? Please refer to the requirements document here and in the files provided to you after downloading this video.

PlayPlay

EmailEmail

This video provides step-by-step information on the preparation of the EYLEA single-dose, pre-filled syringe (PFS) for intravitreal administration.

Planning to use this video in your office or post on your office website? Please refer to the requirements document here and in the files provided to you after downloading this video.

PlayPlay

EmailEmail

A patient education video that explains what DME is and how it occurs, symptoms of DME, vision tests to detect it, the importance of regular eye exams and following an eye care specialist’s treatment plan.

Planning to use this video in your office or post on your office website? Please refer to the requirements document here and in the files provided to you after downloading this video.

PlayPlay

EmailEmail

A patient education video that explains what Wet AMD is and how it occurs, symptoms of Wet AMD, vision tests to detect it, the importance of regular eye exams and following an eye care specialist’s treatment plan.

Planning to use this video in your office or post on your office website? Please refer to the requirements document here and in the files provided to you after downloading this video.

PlayPlay

EmailEmail

Reimbursement

Clear

Billing & Coding

This flashcard can help aid the reimbursement process by providing codes relevant to EYLEA for the treatment of Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Wet Age-related Macular Degeneration (AMD), or Macular Edema following Retinal Vein Occlusion (MEfRVO).

EmailEmail

This letter provides an example of the types of information that may be provided when appealing a dosing denial from a patient’s health plan for EYLEA.

EmailEmail

This letter provides an example of the types of information that may be provided when appealing a bilateral injection denial from a patient’s health plan for EYLEA treatment.

EmailEmail

This letter provides an example of the types of information that may be provided when appealing a claims denial from a patient’s health plan for EYLEA treatment.

EmailEmail

This letter provides an example of the types of information that may be provided when appealing a prior authorization denial from a patient’s health plan for EYLEA treatment.

EmailEmail

This letter provides an example of the types of information that may be provided when responding to a request from a patient’s health plan to provide a letter of medical necessity for EYLEA treatment.

EmailEmail

This letter provides an example of the types of information that may be provided when responding to a step-edit request from a patient’s health plan to provide a letter of medical necessity for EYLEA treatment.

EmailEmail

CMS

This flashcard includes examples of the CMS 1450 form used by hospital outpatient departments and the CMS 1500 form used by physician offices for Medicare billing.

EmailEmail

EYLEA4U®

A reimbursement resource explaining the information needed to complete the EYLEA4U Enrollment Form and understand the results report of a Benefit Investigation (BI).

EmailEmail

A brochure that explains the resources available to eligible patients through EYLEA4U®—a comprehensive patient support program.

EmailEmail

This form allows physicians to enroll patients in EYLEA4U® and request support, including a Benefit Investigation (BI), appeals support, prior authorization (PA), and claims assistance.

English

EmailEmail

The form allows physicians and their Spanish-speaking patients to enroll in EYLEA4U® and request support, including a Benefits Investigation (BI), appeals support, prior authorization (PA), and claims assistance.

Spanish

EmailEmail

Clear

Email Share

To share your selected resources please fill out the information below.

Please enter a valid recipient email address
Please enter your name
Please enter a valid email address

Support for the reimbursement process.
Reimbursement Support

Get information about navigating the
reimbursement process. Find enrollment forms, learn about PA assistance, and more.

See the details
Product support for EYLEA® (aflibercept) Injection.
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

Learn how it works
EYLEA news, events, and more.
About EYLEA

See how EYLEA is backed
by 8 pivotal clinical studies.

View the results
See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.